Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III TrialMarc Ychou, P. Rougier, Valérie Boige et al.|Journal of Clinical Oncology|2011Cited by 2.1k
Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trialThierry Conroy, Jean‐Baptiste Bachet, Jean-François Bosset et al.|The Lancet Oncology|2021Cited by 1.3k
Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS StudyJosep M. Llovet, Joong‐Won Park, Ian Walters et al.|Journal of Clinical Oncology|2013Cited by 596
Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trialThierry Conroy, Antoine Adenis, Marie‐Pierre Galais et al.|The Lancet Oncology|2014Cited by 446
Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trialThierry Conroy, Christophe Borg, Florence Castan et al.|Annals of Oncology|2024Cited by 187